Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 21, 2007

Morphotek Signs Development and Clinical Supply Deal with CMC Biopharmaceuticals

  • Morphotek okayed an agreement with CMC Biopharmaceuticals for GMP manufacturing and regulatory documentation support of MORAb-028, a therapeutic antibody targeting advanced melanoma and other cancers.

    MORAb-028 is a human IgM mAb that specifically recognizes a cell surface antigen over-expressed on a significant fraction of metastatic melanoma, brain cancers, and non-small-cell-lung carcinoma, according to Morphotek.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »